Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes and Transactions
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on February 10, 2011. The transaction price was $38.13 per ADR. The specific allocations for notified individuals were:
- Dr K Belmonte: 8 ADRs
- Mr W C Louv: 18 ADRs
- Dr M M Slaoui: 11 ADRs
- Dr D Pulman: 36 ADRs
- Mr E Gray: 28 ADRs
- Ms D Connelly: 2 ADRs
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the US Retirement Savings Plan re-valuation on the company's overall equity structure.
- Confirm the current market price of GSK Ordinary share ADRs relative to the $38.13 transaction price cited.
- Review the full list of directors and managerial personnel to ensure all relevant transactions are disclosed.